ライフサイエンスコーパス: abciximab

1 eta3 blocking with the aggregation inhibitor abciximab.

2 alloon angioplasty versus stenting, each +/- abciximab.

3 plasty versus stenting, each with or without abciximab.

4 A + abciximab, stenting alone, or stenting + abciximab.

5 ere randomly assigned to receive acolysis or abciximab.

6 ned stenting were randomized to tirofiban or abciximab.

7 Of 181 enrolled, 92 received acolysis and 89 abciximab.

8 international U (IU)/kg alone or followed by abciximab.

9 nd tirofiban, but had the opposite effect on abciximab.

10 ssigned a bolus and infusion of tirofiban or abciximab.

11 parin and GP IIb/IIIa inhibitor therapy with abciximab.

12 pen occluded arteries (GUSTO-IV) trials with abciximab.

13 dy that recognized platelets sensitized with abciximab.

14 se tenecteplase (TNK) and half-dose TNK plus abciximab.

15 otection from major ischemic events than did abciximab.

16 y derive the greatest mortality benefit from abciximab.

17 five patients received tirofiban followed by abciximab.

18 noninferiority of tirofiban as compared with abciximab.

19 Fifteen patients received only abciximab.

20 cardial infarction in patients randomized to abciximab.

21 p = 0.003) suggests a mortality benefit with abciximab.

22 n patients received eptifibatide followed by abciximab.

23 y between two such inhibitors, tirofiban and abciximab.

24 of that rise is diminished by periprocedural abciximab.

25 cally relevant concentrations of aspirin and abciximab.

26 eeding in women was similar with and without abciximab.

27 d 16.0% to 9.9% (p<0.001) in women receiving abciximab.

28 th reduced-dose thrombolysis and concomitant abciximab.

29 2.7% to 6.5% (p<0.001) in women treated with abciximab.

30 .0% to 2.5% (p = 0.03) in women treated with abciximab.

31 but not all pharmacological properties with abciximab.

32 entional centre with half-dose reteplase and abciximab.

33 fibatide compared with patients treated with abciximab.

34 er stenting or balloon angioplasty, each +/- abciximab.

35 In vitro, increasing concentrations of abciximab (0% to 100% receptor occupancy) were tested.

36 rt) or the combination of a standard dose of abciximab (0.25 mg/kg bolus, 0.125 microg/kg per minute

37 h addition of the antibodies 7E3 and Reopro (abciximab) (10 microg/mL), accompanied by a 40% to 70% r

38 nts after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 percent after stenting, and 10.2 percent

39 18 antibody had an effect similar to that of abciximab (16.5+/-0.4%).

40 vs. 4.8%, p = 0.91) and abciximab versus no abciximab (4.3% vs. 5.0%, p = 0.63).

41 incidence of gastrointestinal bleeding with abciximab (4.8% vs. 2.8%, p = 0.01).

42 d to intracoronary compared with intravenous abciximab (54.4; interquartile range: 35.1 to 78.2 vs. 3

43 hen added to VSMCs exposed to MMs and M-CSF, abciximab (7 microg/mL) significantly reduced VSMC apopt

44 %; stent/placebo, 15.8%; balloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P<0.001).

45 lloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P<0.001).

46 0/microL]) within a few hours of being given abciximab a second time showed that each had a strong im

47 nts given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine spe

48 Abciximab, a derivative of the murine mAb 7E3, protects

49 Abciximab, a platelet GP IIb/IIIa receptor inhibitor, ha

50 n angioplasty (PTCA) and abciximab versus no abciximab according to a 2-by-2 factorial design.

51 uced doses of either alteplase or reteplase, abciximab achieved 91% and 83% inhibition of 5 and 20 mi

52 tion myocardial infarction, as compared with abciximab administered immediately before the procedure

53 Whether intralesional abciximab administration and thrombus aspiration confer

54 benefit of intracoronary versus intravenous abciximab administration on myocardial damage and/or rep

55 and with aggregometry for up to 1 week after abciximab administration.

56 Ia receptor blockade in the first week after abciximab administration.

57 ry, and the frequency of stent deployment or abciximab administration.

58 xaparin before PCI and a 12-hour infusion of abciximab after PCI.

59 ded a similar level of overall protection to abciximab against the composite of death, myocardial inf

60 eplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improv

61 rapy patients and one of the 15 who received abciximab alone had minor bleeding.

62 teplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outc

63 ng and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<

64 ys greater than or equal to that achieved by abciximab alone.

65 ban are specific for alphaIIb/beta3, whereas abciximab also exhibits cross-reactivity with the alphav

66 Patients randomized to intracoronary abciximab also had a significant reduction in absolute i

67 Abciximab and 7E3, the anti-beta(3) integrin monoclonal

68 atients are specific for murine sequences in abciximab and are capable of causing life-threatening th

69 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

70 t-PCI electrocardiograms from the Controlled Abciximab and Device Investigation to Lower Late Angiopl

71 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

72 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

73 tilized for score derivation (the Controlled Abciximab and Device Investigation to Lower Late Angiopl

74 n = 700) in two substudies of the Controlled Abciximab and Device Investigation to Lower Late Angiopl

75 The Controlled Abciximab and Device Investigation to Lower Late Angiopl

76 mg intravenous bolus), or half-dose TNK plus abciximab and either UFH (bolus 40 U/kg; infusion 7 U/kg

77 An interaction was observed between abciximab and embolic protection (P<0.05), favoring comb

78 ed models, no significant difference between abciximab and eptifibatide was observed with respect to

79 ns were also less sensitive to inhibition by abciximab and eptifibatide.

80 065 patients to intracoronary or intravenous abciximab and found similar rates of major adverse cardi

81 Treatment with abciximab and low-dose, weight-adjusted heparin during p

82 es after primary PCI are bolus intracoronary abciximab and manual aspiration thrombectomy.

83 s, early PCI facilitated by a combination of abciximab and reduced-dose reteplase was safe and effect

84 Combination therapy (abciximab and reteplase) did not reduce mortality over 1

85 e compared to those receiving combination of abciximab and reteplase.

86 Abciximab and specific inhibitors of the Mac-1 receptor

87 mposite end point for patients not receiving abciximab and the need for TVR among all patients.

88 Intralesional abciximab and thrombus aspiration may have long-term ben

89 red locally at the infarct lesion site vs no abciximab and to manual aspiration thrombectomy vs no th

90 locally at the infarct lesion site versus no abciximab and to manual thrombus aspiration versus no as

91 et glycoprotein IIb/IIIa receptor inhibitor (abciximab) and a half dose of a plasminogen activator (r

92 le for the lack of a consistent benefit with abciximab, and describes future directions for clinical

93 Doses of eptifibatide, abciximab, and tirofiban that inhibited platelet aggrega

94 had an additive effect on the inhibition by abciximab (anti-glycoprotein (GP) IIb/IIIa antibody).

95 ibody 7E3 from which the murine sequences in abciximab are derived; and (2) the "normal" antibodies c

96 ocytopenia so that the beneficial effects of abciximab are not lost by premature termination of thera

97 The use of abciximab as an adjunct during complex infrainguinal art

98 rial, we compared early and late outcomes by abciximab assignment among 2082 patients randomized in a

99 ients with STEMI treated by thrombolysis and abciximab at a non-interventional hospital to immediate

100 gned patients to receive either tirofiban or abciximab before undergoing percutaneous coronary revasc

101 Abciximab binds alpha(IIb)beta(3) on platelets and alpha

102 Abciximab binds Mac-1 (CD11b/CD18) on MMs.

103 benefits of intracoronary versus intravenous abciximab bolus administration on infarct size and reper

104 s randomized to intracoronary or intravenous abciximab bolus at the time of primary PCI.

105 The intracoronary abciximab bolus did not reduce the primary endpoint in p

106 Administration of an intracoronary abciximab bolus during primary percutaneous coronary int

107 protein IIb/IIIa (GP IIb/IIIa) blockade with abciximab bolus plus 12-h infusion reduces mortality aft

108 tients shows a mortality benefit provided by abciximab bolus plus 12-h infusion.

109 ghty patients each had received a placebo or abciximab bolus plus a 12-hour infusion.

110 c patients, intracoronary versus intravenous abciximab bolus was associated with a significantly redu

111 isk for developing thrombocytopenia if given abciximab by screening for antibodies that recognize 7E3

112 Administered after tirofiban, abciximab caused a significant further decline in platel

113 Administered after eptifibatide, abciximab caused a significant further reduction in plat

114 ling; pharmacological therapy (cyclosporine, abciximab, clopidogrel, tirofiban, erythropoietin, throm

115 b or placebo (p = 0.27 for interaction among abciximab/clopidogrel and placebo/clopidogrel treatment

116 IgG antibodies reactive with abciximab-coated platelets were also found in 77 (74%) o

117 Fab fragments and, although they react with abciximab-coated platelets, appear not to cause signific

118 of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic

119 this enhanced level of platelet activation, abciximab, combined with a reduced-dose thrombolytic, in

120 of both major and minor bleeding events with abciximab compared with men, major bleeding in women was

121 Patients randomized to intracoronary abciximab compared with no abciximab had a significant r

122 r of follow-up, treatment with intralesional abciximab compared with no abciximab was associated with

123 iabetic patients randomized to intracoronary abciximab compared with those randomized to intravenous

124 Coronary stenting with abciximab, compared with stenting alone or balloon angio

125 her ligands mimicking small molecular drugs, abciximab cross-reacts with integrin alphavbeta3 and alp

126 ilable: the monoclonal antibody Fab fragment abciximab, cyclic peptides based on the Arg-Gly-Asp (RGD

127 Abciximab decreases the mortality of diabetic patients t

128 andomized in a 2x2 factorial design to bolus abciximab delivered locally at the infarct lesion site v

129 x 2 factorial design to bolus intracoronary abciximab delivered locally at the infarct lesion site v

130 significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion site but not b

131 However, abciximab does not have proven efficacy in medical manag

132 in a placebo-controlled, randomized trial of abciximab during angioplasty.

133 ze the effects of repeated administration of abciximab during intervention.

134 valuated the clinical efficacy of adjunctive abciximab during mechanical or pharmacologic reperfusion

135 s have evaluated the efficacy of concomitant abciximab during mechanical reperfusion therapy in the s

136 ng 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared

137 s with acute STEMI were allocated to receive abciximab either in the ambulance (ambulance group, n=12

138 or IIb/IIIa receptor antagonists (tirofiban, abciximab, eptifibatide); or DTIs (r-hirudin, bivalirudi

139 s of glycoprotein (GP) IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban) and other inhibi

140 Three such alphaIIbbeta3 antagonists, abciximab, eptifibatide, and tirofiban, received Food an

141 Administration of abciximab, eptifibatide, or tirofiban at doses recommend

142 ercutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in t

143 Our objective was to determine whether abciximab, eptifibatide, or tirofiban inhibited ligand b

144 r without fixation; (3) the slow off-rate of abciximab exposes only a small proportion of unblocked G

145 ombination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%;

146 ts in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group,

147 on-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in pat

148 toms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI.

149 rinogen receptor antagonists eptifibatide or abciximab failed to become potentiated by heparin, demon

150 ters in the United States who were receiving abciximab for at least a second time during percutaneous

151 equire PCI and may benefit from switching to abciximab, for which long-term benefits have been report

152 oved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-

153 an group than among the 2411 patients in the abciximab group (7.6 percent vs. 6.0 percent; hazard rat

154 ith 468 (5.6%) in the combined reteplase and abciximab group (odds ratio 0.95 [95% CI 0.83-1.08], p=0

155 in interleukin-6 levels was 76% less in the abciximab group (P<0.001); and the rise in tumor necrosi

156 farction between the tirofiban group and the abciximab group was significant (6.9 percent and 5.4 per

157 ned, however; aggregate 1-year costs for the abciximab group were 1244 dollars greater than for stand

158 ongestive heart failure in the intracoronary abciximab group.

159 significant differences between placebo and abciximab groups.

160 etween the intracoronary and the intravenous abciximab groups.

161 to intracoronary abciximab compared with no abciximab had a significant reduction in 30-day infarct

162 or balloon angioplasty, each with or without abciximab, had CK levels determined at baseline and at 8

163 e percutaneous coronary intervention trials, abciximab has been more efficacious than the other paren

164 Abciximab has well-established clinical benefits in nume

165 Abciximab has well-established clinical benefits in perc

166 ofiban and 345 (14.3%) patients who received abciximab (hazard ratio 1.04, 95% CI 0.90-1.21; p=0.591)

167 independently reduced by balloon angioplasty/abciximab (hazard ratio, 0.51; P<0.001) and stent/abcixi

168 imab (hazard ratio, 0.51; P<0.001) and stent/abciximab (hazard ratio, 0.60; P=0.02) but was not affec

169 oland were treated with half-dose reteplase, abciximab, heparin, and aspirin, and randomly assigned t

170 The aim of the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial In

171 Administration of abciximab immediately after tirofiban or eptifibatide th

172 ting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing prima

173 h STEMI, the administration of intracoronary abciximab improved the effectiveness of primary PCI comp

174 andomized to stenting with either placebo or abciximab in addition to aspirin and heparin.

175 Use of abciximab in combination with administration of thrombol

176 fective compared to that of selective use of abciximab in only those patients requiring percutaneous

177 t with tirofiban or eptifibatide followed by abciximab in patients undergoing percutaneous coronary i

178 ffect of reteplase alone with reteplase plus abciximab in patients with acute myocardial infarction.

179 vestigate whether in-ambulance initiation of abciximab in patients with ST-segment elevation myocardi

180 Early ambulance administration of abciximab in STEMI did not improve either STR or TIMI fl

181 ho received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662

182 is article provides an update of the role of abciximab in the treatment for ACS based on the results

183 The cost-effectiveness of abciximab in this setting is uncertain and depends prima

184 a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2x2 factorial design.

185 Other documented effects of abciximab include acute dethrombosis, reduction of throm

186 Compared with standard anticoagulation, abciximab increased initial procedural costs by 1122 dol

187 The alphaIIbbeta3 antagonist, abciximab, inhibited binding without affecting the unbin

188 widely used integrin alphaIIbbeta3 inhibitor abciximab is a chimeric mouse/human antibody that induce

189 s whether the use of eptifibatide instead of abciximab is associated with a difference in outcomes of

190 Abciximab is presently under evaluation in the treatment

191 h stenting alone or balloon angioplasty with abciximab, is associated with improved survival and is a

192 ed controlled trials suggest that the use of abciximab may be associated with a survival advantage in

193 Ib/IIIa, avbeta3, and alphaMbeta2 receptors, abciximab may reduce inflammatory processes.

194 egional consortium and who were treated with abciximab (n = 729) or with eptifibatide (n = 2,812).

195 imab (n=528), stenting (n=512), and stenting+abciximab (n=524).

196 d to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528), stenting (n=512), and stenting+abcixi

197 n=8260) or half-dose reteplase and full-dose abciximab (n=8328).

198 erapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who receiv

199 ther facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone signific

200 plasty + abciximab, stenting, and stenting + abciximab, normal myocardial perfusion was restored in 1

201 ve difference in TVR rates (ie, no effect of abciximab on reducing restenosis).

202 f performed; or 2) wait, and selectively use abciximab only in patients who ultimately undergo PCI.

203 vitro inhibition of platelet aggregation by abciximab or correlate with clinical events.

204 bolus) with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide) (n = 3011).

205 bolus), with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide).

206 pretreatment, irrespective of assignment to abciximab or placebo (p = 0.27 for interaction among abc

207 randomly assigned to adjunctive therapy with abciximab or placebo at the beginning of the study.

208 planned stenting were randomized to receive abciximab or tirofiban.

209 [alone or in combination], eptifibatide, or abciximab) or anticoagulants (antithrombin dabigatran et

210 er integrins, the pharmacodynamic profile of abciximab, or other effects.

211 cyclic RGD peptide, the monoclonal antibody abciximab, or the alpha v beta 3-specific cyclic peptide

212 01 to 1.57, demonstrating the superiority of abciximab over tirofiban; P=0.038).

213 enting, and 10.2 percent after stenting plus abciximab (P<0.001).

214 ed survival were assignment to stenting with abciximab (p=0.027) and greater preprocedural stenosis (

215 Del-1 (P=0.027) and by annexin A5 (P=0.027), abciximab (P=0.027), a monoclonal antibody to integrin a

216 the tirofiban-RESTORE regimen compared with abciximab (P=0.028) and eptifibatide regimens (P=0.0001)

217 t 30 days was 25% with acolysis and 12% with abciximab (P=0.036), attributable mainly to a greater fr

218 fter PTCA to 5.2 percent after stenting plus abciximab, P<0.001).

219 ieved in 63% of acolysis patients and 82% of abciximab patients (P=0.008).

220 d in 53.8% of acolysis patients and 73.1% of abciximab patients (P=0.014).

221 ntion (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilita

222 Aspirin plus ticlopidine, as well as abciximab, protected 45%-88% of animals against S. gordo

223 r the combination of half-dose reteplase and abciximab provides any propitious benefits over standard

224 women in the CADILLAC trial, the addition of abciximab reduced 30-day TVR without increasing bleeding

225 facilitating accelerated hospital discharge, abciximab reduced length of stay by approximately 0.6 da

226 Abciximab reduced the occurrence of platelet-rich emboli

227 olytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with

228 nti-platelet and anti-thrombotic activities, abciximab reduces thrombus formation and hence minimizes

229 The abciximab regimen, however, showed increasingly varied a

230 Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of per

231 vation or adhesion (clopidogrel (Plavix) and abciximab (ReoPro), respectively).

232 ed in the United States and other countries: abciximab (ReoPro; the Fab fragment of a chimeric human-

233 randomized to intracoronary abciximab vs no abciximab, respectively, and in 174 and 179 patients ran

234 haIIbbeta3 receptor inhibitors cangrelor and abciximab, respectively, both in vitro--by incubating th

235 and 42.7% assigned to PTCA alone and PTCA + abciximab, respectively.

236 p = 0.94) of men treated with placebo versus abciximab, respectively.

237 = 0.003) of men treated with placebo versus abciximab, respectively.

238 with acute coronary syndromes (ACS; n=3025), abciximab resulted in lower rates of myocardial infarcti

239 domly assigned to undergo PTCA alone, PTCA + abciximab, stenting alone, or stenting + abciximab.

240 nts randomized to angioplasty, angioplasty + abciximab, stenting, and stenting + abciximab, normal my

241 the net incremental baseline cost of these 2 abciximab strategies was $583 with low-dose weight-adjus

242 e protein was 32% less in patients receiving abciximab than placebo (P=0.025); the rise in interleuki

243 noninferiority of tirofiban as compared with abciximab, the findings demonstrated that tirofiban offe

244 Ia inhibitors have shown benefit in ACS, but abciximab, the more expensive GP IIb/IIIa inhibitor, may

245 the MultiLink stent (512), or stenting plus abciximab therapy (524).

246 undergo PTCA alone (518 patients), PTCA plus abciximab therapy (528), stenting alone with the MultiLi

247 rosis factor-alpha levels was 100% less with abciximab therapy (P=0.112).

248 e incidence of pseudothrombocytopenia during abciximab therapy administered for percutaneous coronary

249 nosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6+/-

250 centers, stent implantation (with or without abciximab therapy) should be considered the routine repe

251 rom 14 patients undergoing PTCA who received abciximab therapy, ticlopidine therapy, or both treatmen

252 Treatment with intralesional abciximab, thrombus aspiration, or both therapies compar

253 e current study was to determine if combined abciximab/ticlopidine therapy inhibits arterial thrombos

254 Of the 3 treatments, combined abciximab/ticlopidine therapy produced the most consiste

255 (1) dissociation of GP IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide, or xemilofiban) from

256 Thus, addition of 3 microg/mL abciximab to 1.0 anti-IIa/Xa U/mL heparin and to 1.0 ant

257 The addition of abciximab to primary stenting significantly reduced the

258 nia occurred in 3.7% (95% CI: 3.2%, 4.2%) of abciximab-treated patients and in 1.8% (95% CI: 1.3%, 2.

259 0.89; P:=0.010) in both placebo-treated and abciximab-treated patients.

260 icantly (18.4% for controls versus 16.9% for abciximab-treated patients; relative risk, 0.92; 95% CI,

261 y and abciximab treatment (n=1052) versus no abciximab treatment (n=1030).

262 l of primary stenting versus angioplasty and abciximab treatment (n=1052) versus no abciximab treatme

263 Abciximab treatment alone inhibited mural thrombosis for

264 Abciximab treatment did not affect the composite end poi

265 Adjunctive abciximab treatment during primary percutaneous coronary

266 Abciximab treatment was associated with a significant re

267 rombosis also was significantly reduced with abciximab treatment.

268 significant interaction between stenting and abciximab treatment.

269 y reocclusion at 7 months were unaffected by abciximab treatment.

270 ent with randomized clinical trials of first abciximab treatment.

271 A total of 564 patients (274 in abciximab/UFH group vs. 290 in bivalirudin group) were e

272 val model, the risk ratio for mortality with abciximab use compared with placebo was 0.642 (95% confi

273 ents with ACS undergoing stent implantation, abciximab use compared with tirofiban results in greater

274 The beneficial reduction in mortality with abciximab use in diabetics classified as insulin-requiri

275 In adjusted models, contraindicated abciximab use in patients with thrombocytopenia (hazard

276 Contraindicated abciximab use was not significantly associated with 30-d

277 nd 5.7 percent (P=0.01), both independent of abciximab use.

278 us angioplasty (4.5% vs. 4.8%, p = 0.91) and abciximab versus no abciximab (4.3% vs. 5.0%, p = 0.63).

279 enting versus balloon angioplasty (PTCA) and abciximab versus no abciximab according to a 2-by-2 fact

280 o the combination of half-dose reteplase and abciximab versus those randomized to reteplase.

281 and 172 patients randomized to intracoronary abciximab vs no abciximab, respectively, and in 174 and

282 he incidence of in-hospital death (4.1% with abciximab vs. 3.5% with eptifibatide, p = 0.39), recurre

283 A 0.25-mg/kg bolus of abciximab was administered at the site of the infarct le

284 Abciximab was administered by means of a weight-base nom

285 ith intralesional abciximab compared with no abciximab was associated with a lower rate of death (1.4

286 The relative benefit of abciximab was consistent regardless of age, sex, the pre

287 a(3) integrin monoclonal antibody from which abciximab was derived, bound alpha(v)beta(3) on HASMCs i

288 Although combined reteplase and abciximab was not superior to standard reteplase, the 0.

289 Abciximab was reasonably cost-effective (cost-effectiven

290 ticipated interaction between Angioguard and abciximab was seen, with combination therapy better than

291 ment in glomerular filtration rate; although abciximab was superior to placebo (0+/-27% versus -10+/-

292 Abciximab was used in conjunction with recanalization te

293 g with embolic protection, and stenting with abciximab were associated with a decline in glomerular f

294 8758 (P:=0.005) and $9092 (P:=0.176) for the abciximab with low-dose and standard-dose heparin arms,

295 The impact of HPR on clinical outcomes in abciximab with UFH versus bivalirudin treated non-ST-seg

296 For abciximab with UFH, the incidence of the efficacy endpoi

297 wed similar efficacy profiles as compared to abciximab with UFH.

298 myocardial infarction patients that received abciximab with unfractionated heparin (UFH) or bivalirud

299 r better outcomes with tirofiban relative to abciximab, with fewer adverse hematologic and hemorrhagi

300 prising conventional therapy plus a bolus of abciximab within 1 h before PCI followed by a 12-h infus